Hong Kong market could open cash flood gates for U.S. biotechs

with No Comments

(Reuters) – When U.S. biotech startup Sorrento Therapeutics named ex-Lehman Brothers executive Jiong Shao as its new finance chief about two months ago, it was widely seen as a move driven by his background in raising capital for Alibaba and Tencent.

from Reuters: Business News https://ift.tt/2ybew2g http://www.reuters.com

Leave a Reply